<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03832699</url>
  </required_header>
  <id_info>
    <org_study_id>0013-19-WOMC</org_study_id>
    <nct_id>NCT03832699</nct_id>
  </id_info>
  <brief_title>Oral Dydrogesterone vs. Vaginal Micronized Progesterone for Luteal Phase Support in Frozen-thawed Embryo Transfer</brief_title>
  <official_title>Oral Dydrogesterone vs. Vaginal Micronized Progesterone for Luteal Phase Support in Frozen-thawed Embryo Transfer: a Non-inferiority Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wolfson Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wolfson Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current trial is intended to assess the efficacy of oral versus vaginal progesterone for
      luteal support in frozen IVF cycles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Progesteron is used for luteal phase support in IVF cycles. Progesterone can be administered
      vaginally and orally. Duphaston is an oral progesterone drug, which has recentlly been proven
      effective in fresh cycle IVF. Yet, less is known regarding its efficacy in frozen cycle IVF.
      Thus, the objective of our trial is to compare the efficacy of vaginal and oral progesterone
      in frozen IVF cycles.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Birth of a live infant after 24 weeks gestation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>Outcome assesed 6-7 weeks following treatment</time_frame>
    <description>Viable pregnancy as demonstrated by ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>Outcome assessed 6-7 weeks following treatment</time_frame>
    <description>Number of gestational sacs divided by number of embryos transferred (percentage)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>ART</condition>
  <arm_group>
    <arm_group_label>Oral progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dydrogesterone 10 MG</intervention_name>
    <description>Oral progesterone 10 mg TID</description>
    <arm_group_label>Oral progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endometrin 100Mg Vaginal Insert</intervention_name>
    <description>Vaginal Endometrin 100 mg twice daily</description>
    <arm_group_label>Vaginal progesterone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 18-39

          -  Modified natural cycle (induction of ovulation with HCG)

          -  Consent to participation

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hadas Ganer Herman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Edith Wolfson Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hadas Ganer Herman, MD</last_name>
    <phone>972526206696</phone>
    <email>hadassganer@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Edith Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <zip>5822012</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hadas Ganer Herman, MD</last_name>
      <phone>9720526206696</phone>
      <email>hadassganer@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 5, 2019</study_first_submitted>
  <study_first_submitted_qc>February 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2019</study_first_posted>
  <last_update_submitted>June 6, 2019</last_update_submitted>
  <last_update_submitted_qc>June 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wolfson Medical Center</investigator_affiliation>
    <investigator_full_name>Hadas Ganer Herman</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dydrogesterone</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

